Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

Table 3

Characteristics and outcomes of six patients with clinically suspected drug-resistant CMV.

Patient no.	Age/sex	Clinical symptoms	Drug/regimen	Duration of drug exposure	CMV DNA copy no. (log10/mL)
					At the beginning of therapy	After therapy
1	43/F	Fever, leukopenia, thrombocytopenia, pneumonia	VGCV/treatment	3 weeks	4.2	2.1
2	47/F	Fever, leukopenia, graft rejection	GCV/treatment and maintenance	2 weeks treatment and 3 months maintenance	4.1	2.3
3	60/M	Leukopenia	VGCV/prophylaxis, GCV & VGCV/treatment	2 weeks prophylaxis, 2 weeks + 3 months treatment	4.9	3.9
4	54/F	Fever, leukopenia	GCV/treatment	2 weeks	4.8	3.5
5	55/F	Fever, leukopenia, high creatinene, diarrhoea	GCV & VGCV/treatment	3 weeks	2.8	1.7
6	34/F	Fever, leukopenia, renal failure, bleeding	GCV/prophylaxis, GCV & VGCV/treatment	2 week prophylaxis, 3 months treatment	2.9	1.7